Coronary Heart Disease (CHD)CPET-PCHDNCT07534410
The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study(CPETPCAD)
An observational study of Coronary Heart Disease (CHD), run by Xinjiang Medical University.
Trial summary
Parameters related to cardiopulmonary exercise testing (CPET) are important objective indicators for evaluating cardiopulmonary function in patients with coronary heart disease. However, the clinical application of CPET parameters in the prognostic assessment of patients with coronary heart disease remains unclear. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Heart Disease (CHD)
- How many people
- 15,000 participants
- Where
- No sites listed yet
- Study dates
- 7 Apr 2026to 30 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients diagnosed with coronary heart disease in our hospital and who have completed cardiopulmonary exercise testing.
Who may be able to join
- Our hospital has diagnosed coronary heart disease and conducted cardiopulmonary exercise tests.
- Patients with complete clinical data.
Who cannot join
- Uncontrolled heart failure (NYHA classification Ⅲ-IV grade).
- Complications, such as moderate to severe anemia, tumors and lung diseases.
- Complicated with valvular heart disease.
- Unable to reach the anaerobic threshold during exercise.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study
Parameters related to cardiopulmonary exercise testing (CPET) are important objective indicators for evaluating cardiopulmonary function in patients with coronary heart disease. However, the clinical application of CPET parameters in the prognostic assessment of patients with coronary heart disease remains unclear. This is a retrospective cohort study designed to systematically collect real-world clinical data and long-term follow-up outcomes of patients with coronary heart disease. Through standardized follow-up, this study will investigate the association between CPET parameters and adverse clinical outcomes in patients with coronary heart disease, as well as the relevant risk factors.
- Conditions
- Coronary Heart Disease (CHD)
- Medical subject headings
- Coronary Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Coronary Heart Disease Cohort | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cumulative incidence of Major Adverse Cardiovascular Events (MACE)
The proportion of patients who experience an adjudicated Major Adverse Cardiovascular Event (MACE), defined as a composite endpoint consisting of non-fatal myocardial infarction, non-fata
Measured: 1 year
Secondary outcomes (1)
All-cause mortality
Record of deaths from any cause during follow-up. Confirmed by medical records, family follow-up, or national death registration systems.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Apr 2026
- Study start7 Apr 2026 (estimated)
- Primary completion31 Jan 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Coronary Heart Disease (CHD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 15,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xinjiang Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiang Xie, Xinjiang Medical University
- Investigators
- Xiang Xie, PhD, Study chair, First Affiliated Hospital of Xinjiang Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07534410
- Sponsor's protocol ID
- K202512-44
- Acronym
- CPET-PCHD
- Status last verified
- Dec 2025
- First submitted
- 9 Apr 2026
- Last updated
- 16 Apr 2026
- Results posted
- No
- Individual data sharing
- No
Publications
Zhang N, Maitudi M, Lu W. Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial. Clin Ther. 2026 Jun 30:S0149-2918(26)00216-X. doi: 10.1016/j.clinthera.2026.06.004. Online ahead of print.
PubMed 42379943
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT07534410
- Acronym / sponsor ID
- CPET-PCHD / K202512-44
- Conditions
- Coronary Heart Disease (CHD)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 15,000 participants (estimated)
- Lead sponsor
- Xinjiang Medical UniversityUniversity, hospital or other
- Study start
- 7 Apr 2026 (estimated)
- Primary completion
- 31 Jan 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 16 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Parameters related to cardiopulmonary exercise testing (CPET) are important objective indicators for evaluating cardiopulmonary function in patients with coronary heart disease. However, the clinical application of CPET parameters in the prognostic assessment of patients with coronary heart disease remains unclear. This is a retrospective cohort study designed to systematically collect real-world clinical data and long-term follow-up outcomes of patients with coronary heart disease. Through standardized follow-up, this study will investigate the association between CPET parameters and adverse clinical outcomes in patients with coronary heart disease, as well as the relevant risk factors.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Coronary Heart Disease Cohort | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with coronary heart disease in our hospital and who have completed cardiopulmonary exercise testing.
Key inclusion criteria (2 listed)
- Our hospital has diagnosed coronary heart disease and conducted cardiopulmonary exercise tests.
- Patients with complete clinical data.
Key exclusion criteria (4 listed)
- Uncontrolled heart failure (NYHA classification Ⅲ-IV grade).
- Complications, such as moderate to severe anemia, tumors and lung diseases.
- Complicated with valvular heart disease.
- Unable to reach the anaerobic threshold during exercise.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cumulative incidence of Major Adverse Cardiovascular Events (MACE)
Time frame: 1 year
The proportion of patients who experience an adjudicated Major Adverse Cardiovascular Event (MACE), defined as a composite endpoint consisting of non-fatal myocardial infarction, non-fata
1 secondary outcome
All-cause mortality
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2026.
- Derived from this study: PubMed 42379943Zhang N, Maitudi M, Lu W. Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial. Clin Ther. 2026 Jun 30:S0149-2918(26)00216-X. doi: 10.1016/j.clinthera.2026.06.004. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for Coronary Heart Disease (CHD)
Not yet recruiting
Autologous Thymus Transplant in Children With Congenital Heart Disease: A Pilot Study
Congenital Heart Disease (CHD)
Not yet recruiting
Hs-CRP-Guided Colchicine Treatment Targets in Very-High-Risk Patients With Coronary Artery Disease After PCI (TARGET-CHD)
Coronary Artery Disease, Atherosclerotic Cardiovascular Disease (ASCVD)
Active, not recruiting
Learning by Heart: The Effectiveness of an EF Training Program for Pre-schoolers With Critical CHD
Congenital Heart Disease, Executive Dysfunction
Not yet recruiting
UltraTrac for Cardiac Output Monitoring in Congenital Heart Disease
Congenital Heart Disease, Cardiac Output
RecruitingPhase 1/2
Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids
Congenital Heart Disease (CHD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xiang Xie, PhD study chair
First Affiliated Hospital of Xinjiang Medical University
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Heart Disease (CHD), run by Xinjiang Medical University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiang Xie, PhD (+86-991-4366892, xiangxie999@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cumulative incidence of Major Adverse Cardiovascular Events (MACE) (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07534410, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.